Shattuck Labs, Inc. (STTK)

Market Cap	54.90M
Revenue (ttm)	6.44M
Net Income (ttm)	-74.42M
Shares Out	47.74M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	420,981
Open	1.020
Previous Close	1.040
Day's Range	1.020 - 1.160
52-Week Range	0.940 - 11.760
Beta	1.78
Analysts	Hold
Price Target	2.00 (+73.91%)
Earnings Date	Nov 14, 2024

About STTK

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: STTK
• Website: https://www.shattucklabs.com

Financial Performance

In 2023, Shattuck Labs's revenue was $1.66 million, an increase of 154.14% compared to the previous year's $652,000. Losses were -$87.30 million, -14.37% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for STTK stock is "Hold." The 12-month stock price forecast is $2.0, which is an increase of 73.91% from the latest price.

Price Target

$2.0

(73.91% upside)

Analyst Consensus: Hold